NEXT

About

Based in Hangzhou, China, and founded in 2021, Hangzhou Qiantang Longyue Biotechnology Co., Ltd., trading as NEXT, focuses on the research, development, and manufacturing of innovative drug delivery systems, pharmaceutical packaging materials, and drug-device combination products. In April 2022, it obtained ISO13485 system certification. It obtained ISO 13485 certification in April 2022 and received its first medical device registration certificate in June 2022. In September 2026, the company closed a venture funding round led by HM Capital, with participation from Bioinsight Ventures, Zhejiang University Holding, and others. NEXT has developed four core technology platforms supporting a range of drug delivery and pharmaceutical packaging solutions. Its product portfolio includes drug delivery systems, pre-filled systems, vaccine delivery systems, ophthalmic drug delivery systems, aesthetic injection delivery systems, vial reconstitution and dispensing systems, customized development services, and drug-device combination products. The company generates revenue through the design, development, manufacture, and sale of drug delivery devices, pharmaceutical packaging materials, prefilled systems, and drug-device combination products. The company will use the funding in September 2026 to enhance its R&D and industrialization capabilities and refine its overall strategic layout in the field of innovative drug-device combination packaging and drug delivery systems.